Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues

Expert Review of Gastroenterology and Hepatology

Volumn 11, Issue 3, 2017, Pages 259-268

  Marcellin, Fabienne ^a,b   Roux, Perrine ^a,b   Protopopescu, Camelia ^a,b   Duracinsky, Martin ^c,d,e   Spire, Bruno ^a,b   Carrieri, Maria Patrizia ^a,b  

^a AIX MARSEILLE UNIV   (France)

^b OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^c Lariboisière Hospital   (France)

^d HÔTEL DIEU   (France)

^e BICÊTRE HOSPITAL   (France)

Author keywords

Chronic infection; direct acting antivirals; drug users; fatigue; hepatitis C; key populations; patient reported outcomes; quality of life; reinfection; risk behaviors

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; DASABUVIR; ELBASVIR PLUS GRAZOPREVIR; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; SIMEPREVIR; SOFOSBUVIR; SOFOSBUVIR PLUS VELPATASVIR;

CHRONIC HEPATITIS C; CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE ACCESS; HIGH RISK BEHAVIOR; HUMAN; INFECTION RISK; MEDICATION COMPLIANCE; MULTICENTER STUDY (TOPIC); PATIENT PREFERENCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRODUCTIVITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SOCIAL INTERACTION; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VIRAL CLEARANCE; DRUG EFFECTS; EMPLOYMENT; HEPACIVIRUS; HEPATITIS C, CHRONIC; PATHOGENICITY; PATIENT-REPORTED OUTCOME; REMISSION; RISK FACTOR; TIME FACTOR;

ANTIVIRAL AGENTS; EFFICIENCY; EMPLOYMENT; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MEDICATION ADHERENCE; PATIENT REPORTED OUTCOME MEASURES; QUALITY OF LIFE; REMISSION INDUCTION; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85012013989     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1080/17474124.2017.1285227     Document Type: Review

References (94)

1. U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry:patient-reported outcome measures:use in medical product development to support labeling claims:draft guidance. Health Qual Life Outcomes. 2006;4:79.
2. Marcellin F, Carrieri MP, Spire B., Choice of therapeutic strategies in the context of HIV infection:key role of patient-reported outcomes. Expert Rev Anti Infect Ther. 2012;10(4):403–406.
3. Marcellin F, Roux P, Winnock M, et al. Using patient-reported outcomes to improve the management of co-infection with HIV and HCV:the ANRS CO13 HEPAVIH cohort. Expert Rev Gastroenterol Hepatol. 2014;8(4):351–358.
4. Chassany O, Sagnier P, Marquis P, et al. Patient-reported outcomes:the example of health-related quality of life - a European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Inf J. 2002;36:209–238.
5. Evon DM. Incorporating patient-reported outcomes into hepatitis C virus treatment studies. Clin Gastroenterol Hepatol. 2014;12(8):1360–1362.
6. Ahmed S, Berzon RA, Revicki DA, et al. The use of patient-reported outcomes (PRO) within comparative effectiveness research:implications for clinical practice and health care policy. Med Care. 2012;50(12):1060–1070.
7. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353–365.
8. Younossi Z, Brown A, Buti M, et al. Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients:an economic model from five European countries. J Viral Hepat. 2016;23(3):217–226.
9. Younossi ZM, Stepanova M, Sulkowski M, et al. Ribavirin-free regimen with sofosbuvir and velpatasvir is associated with high efficacy and improvement of patient-reported outcomes in patients with genotypes 2 and 3 chronic hepatitis C:results from ASTRAL-2 and −3 clinical trials. Clin Infect Dis. 2016;63(8):1042–1048.
10. Younossi ZM, Stepanova M, Pol S, et al. The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C:the SIRIUS study. Liver Int. 2016;36(1):42–48.
11. Younossi ZM, Stepanova M, Feld J, et al. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients:results from ASTRAL-1 placebo-controlled trial. J Hepatol. 2016;65(1):33–39.
12. Younossi ZM, Stepanova M, Sulkowski M, et al. Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus. J Viral Hepat. 2016;23(11):857–865.
13. Younossi ZM, Stepanova M, Henry L, et al. Association of work productivity with clinical and patient-reported factors in patients infected with hepatitis C virus. J Viral Hepat. 2016;23(8):623–630.
14. Younossi ZM, Stepanova M, Afdhal N, et al. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol. 2015;63(2):337–345.
15. Scott J, Gilles L, Fu M, et al. Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin:results from 1161 patients in the QUEST-1, QUEST-2 and PROMISE studies. J Viral Hepat. 2015;22(8):639–650.
16. Palmateer N, Hutchinson S, McAllister G, et al. Risk of transmission associated with sharing drug injecting paraphernalia:analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data. J Viral Hepat. 2014;21(1):25–32.
17. Bradshaw D, Matthews G, Danta M. Sexually transmitted hepatitis C infection:the new epidemic in MSM? Curr Opin Infect Dis. 2013;26(1):66–72.
18. Danta M, Brown D, Bhagani S, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. Aids. 2007;21(8):983–991.
19. Knight R, Roux P, Vilotitch A, et al. Significant reductions in alcohol use after hepatitis C treatment:results from the French ANRS CO13-HEPAVIH cohort. ISBRA-ESBRA 2016 - World Congress on Alcohol and Alcoholism - 2-5 September 2016. Berlin, Germany. (abst 2_51). 2016.
20. Yeung MW, Young J, Moodie E, et al. Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfected patients after hepatitis C therapy:a prospective cohort study. HIV Clin Trials. 2015;16(3):100–110.• One of the few existing studies evaluating changes in patient-reported measures after HCV therapy.
21. Innes HA, McDonald SA, Dillon JF, et al. Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes. Hepatol. 2015;62(2):355–364.
22. Basch E, Abernethy AP, Mullins CD, et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol. 2012;30(34):4249–4255.
23. Powers JH, Howard K, Saretsky T, et al. Patient-reported outcome assessments as endpoints in studies in infectious diseases. Clin Infect Dis. 2016;63(Suppl 2):S52–56.
24. Spiegel BMR, Younossi ZM, Hays RD, et al. Impact of hepatitis C on health related quality of life:a systematic review and quantitative assessment. Hepatol. 2005;41(4):790–800.
25. Obhrai J, Hall Y, Anand BS. Assessment of fatigue and psychologic disturbances in patients with hepatitis C virus infection. J Clin Gastroenterol. 2001;32(5):413–417.
26. Forton DM, Allsop JM, Cox IJ, et al. A review of cognitive impairment and cerebral metabolite abnormalities in patients with hepatitis C infection. Aids. 2005;19(Suppl 3):S53–63.
27. Younossi ZM, Stepanova M, Nader F, et al. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Hepatol. 2014;59(6):2161–2169.
28. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatol. 2002;36(5 Suppl 1):S237–244.
29. Younossi Z, Henry L. Systematic review:patient-reported outcomes in chronic hepatitis C–the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther. 2015;41(6):497–520.•• A comprehensive review of PROs in patients with chronic hepatitis C, with a special focus on results from clinical trials.
30. Buti M, Esteban R. Patient experience in HCV therapy:what really matters. Lancet Gastroenterol Hepatol. 2016;1(2):90–92.
31. Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–483.
32. de Bruin AF, Diederiks JP, de Witte LP, et al. The development of a short generic version of the sickness impact profile. J Clin Epidemiol. 1994;47(4):407–418.
33. Kaplan RM, Ganiats TG, Sieber WJ, et al. The quality of well-being scale:critical similarities and differences with SF-36. Int J Qual Health Care. 1998;10(6):509–520.
34. Feeny D, Furlong W, Boyle M, et al. Multi-attribute health status classification systems. Health Utilities Index. Pharmacoeconomics. 1995;7(6):490–502.
35. Brazier J, Usherwood T, Harper R, et al. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol. 1998;51(11):1115–1128.
36. Brooks R, Rabin R, de Charro F. The measurement and valuation of health status using EQ-5D:a European perspective. Springer Netherlands:Kluwer Academic Publishers. 2003.
37. Younossi ZM, Guyatt G, Kiwi M, et al. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut. 1999;45(2):295–300.
38. Saab S, Ng V, Landaverde C, et al. Development of a disease-specific questionnaire to measure health-related quality of life in liver transplant recipients. Liver Transplant. 2011;17(5):567–579.
39. Kanwal F, Spiegel BMR, Hays RD, et al. Prospective validation of the short form liver disease quality of life instrument. Aliment Pharmacol Ther. 2008;28(9):1088–1101.
40. van der Plas SM, Hansen BE, de Boer JB, et al. The Liver Disease Symptom Index 2.0; validation of a disease-specific questionnaire. Qual Life Res. 2004;13(8):1469–1481.
41. Bayliss MS, Gandek B, Bungay KM, et al. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Qual Life Res. 1998;7(1):39–55.
42. Smets EM, Garssen B, Bonke B, et al. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995;39(3):315–325.
43. Stein KD, Jacobsen PB, Blanchard CM, et al. Further validation of the multidimensional fatigue symptom inventory-short form. J Pain Symptom Manage. 2004;27(1):14–23.
44. Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System:properties, applications, and interpretation. Health Qual Life Outcomes. 2003;1:79.
45. Fisk JD, Ritvo PG, Ross L, et al. Measuring the functional impact of fatigue:initial validation of the fatigue impact scale. Clin Infect Dis. 1994;18(Suppl 1):S79–83.
46. Marcellin F, Protopopescu C, Poizot-Martin I, et al. Short article:fatigue in the long term after HCV treatment in HIV-HCV-coinfected patients:functional limitations persist despite viral clearance in patients exposed to peg-interferon/ribavirin-containing regimens (ANRS CO13-HEPAVIH cohort). Eur J Gastroenterol Hepatol. 2016;28(9):1003–1007.
47. Kleinman L, Mannix S, Yuan Y, et al. Review of patient-reported outcome measures in chronic hepatitis C. Health Qual Life Outcomes. 2012;10:92.
48. Armstrong AR, Herrmann SE, Chassany O, et al. The International development of PROQOL-HCV:an instrument to assess the health-related quality of life of patients treated for hepatitis C virus. BMC Infect Dis. 2016;16(1):443.•• Presentation of the development of a HCV-specific, cross-cultural HRQL scale.
49. Anderson RT, Baran RW, Dietz B, et al. Development and initial psychometric evaluation of the hepatitis C virus-patient-reported outcomes (HCV-PRO) instrument. Qual Life Res. 2014;23(2):561–570.
50. Ware J, Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey:construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220–233.
51. Hassanein T, Cooksley G, Sulkowski M, et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol. 2004;40(4):675–681.
52. Bezemer G, van Gool AR, Verheij-Hart E, et al. Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study. BMC Gastroenterol. 2012;12:11.
53. Kemmer N, Hua L, Andersen JW, et al. Health-related quality of life in subjects with HCV/HIV coinfection:results from ACTG 5178 study. J Viral Hepat. 2012;19(11):792–800.
54. Perrillo R, Rothstein KD, Rubin R, et al. Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C. J Viral Hepat. 2004;11(2):157–165.
55. Snow KK, Bonkovsky HL, Fontana RJ, et al. Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2010;31(7):719–734.
56. Arora S, O’Brien C, Zeuzem S, et al. Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin:impact on health-related quality of life. J Gastroenterol Hepatol. 2006;21(2):406–412.
57. Marcellin F, Préau M, Dellamonica P, et al. Adding HCV treatment to HIV treatment in HIV-HCV coinfected patients:the impact on the different dimensions of fatigue and self-reported side effects. J Pain Symptom Manage. 2007;34(4):413–421.
58. Bernstein D, Kleinman L, Barker CM, et al. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology. 2002;35(3):704–708.
59. Marcellin F, Demoulin B, Spire B, et al. Spontaneous and post-treatment HCV clearance:relationships with health-related quality of life in HIV infection (ANRS-VESPA2 study). Expert Rev Gastroenterol Hepatol. 2015;9(5):701–713.
60. AASLD. Recommendations for Testing, Managing, and Treating Hepatitis C. Available from:http://www.hcvguidelines.org/. (2014).
61. European Association for the Study of the Liver. Electronic address:easloffice@easloffice.eu. EASL Recommendations on Treatment of Hepatitis C. J Hepatol. 2015.
62. Younossi ZM, Stepanova M, Henry L, et al. An in-depth analysis of patient-reported outcomes in patients with chronic hepatitis C treated with different anti-viral regimens. Am J Gastroenterol. 2016;111(6):808–816.
63. Younossi ZM, Stepanova M, Henry L, et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). J Hepatol. 2014;60(4):741–747.
64. Younossi ZM, Stepanova M, Nader F, et al. The patient’s journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens:a study of health-related quality of life. Aliment Pharmacol Ther. 2015;42(3):286–295.
65. Younossi ZM, Stepanova M, Zeuzem S, et al. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin:the VALENCE study. J Hepatol. 2014;61(2):228–234.
66. Younossi ZM, Stepanova M, Sulkowski M, et al. Sofosbuvir and ribavirin for treatment of chronic hepatitis C in patients coinfected with hepatitis C virus and HIV:the impact on patient-reported outcomes. J Infect Dis. 2015;212(3):367–377.
67. Bruchfeld A, Elbavir/grazoprevir treatment of hepatitis C virus infection in patients with chronic kidney disease stage 4/5:clinical, virologic and health-related quality of life outcomes in the C-SURFER study. Presented at the 53rd Congress of the European Renal Association-European Dialysis & Transplant Association (ERA-EDTA). 2016 2016 May21–24. Vienna, Austria
68. Arduino JM, Wang Y, Brown DD, et al. C-EDGE TN:impact of 12-week oral regimen of grazoprevir (GZR, MK-5172)/eLbasvir (EBR, MK-8742) on patient-reported outcomes (PROS) in treatment-naïve patients with chronic hepatitis C virus (HCV) genotype (GT) 1, 4, or 6 infection - AASLD LiverLearning®. 2015. Available from:http://www.aasld.org/liver-learning
69. Arduino JM, Jiang Z, Shaughnessy M, et al. C-EDGE co-Infection:impact of 12-week oral regimen of grazoprevir (GZR, MK-5172)/elbasvir (EBR, MK-8742) on patient-reported outcomes (PROs) in treatment-naïve patients with HCV/HIV co-infection. AASLD LiverLearning®. 2015.
70. Arduino JM, Shibolet O, Litwin AH, et al. C-EDGE CO-STAR:favorable Impact of elbasvir and grazoprevir on health-related quality of life in treatment-naïve HCV-infected persons who inject drugs receiving opioid agonist therapy. EASL 2016 April 14-17. Barcelona. J Hepatol. 2016;64:S403-S404.
71. Younossi ZM, Stepanova M, Charlton M, et al. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis:an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. Lancet Gastroenterol Hepatol. 2016;1(2):122–132.
72. Kwo P, Gitlin N, Nahass R, et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis:OPTIMIST-1, a phase 3, randomized study. Hepatol. 2016;64(2):370–380.
73. Lawitz E, Matusow G, deJesus E, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis:a phase 3 study (OPTIMIST-2). Hepatol. 2016;64(2):360–369.
74. Grebely J, Mauss S, Brown A, et al. Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy:analysis of Phase 3 ION trials. Clin Infect Dis. 2016;63(11):1405–1411.
75. Younossi ZM, Stepanova M, Henry L, et al. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2014;12(8):1349–1359.e13.
76. Younossi ZM, Stepanova M, Feld J, et al. Sofosbuvir and velpatasvir combination improves outcomes reported by patients with HCV infection, without or with compensated or decompensated cirrhosis. Clin Gastroenterol Hepatol. 2016. pii:S1542-3565(16)31050-3. doi:10.1016/j.cgh.2016.10.037. [Epub ahead of print].
77. InfoHep. Hepatitis C treatment factsheet Viekirax (paritaprevir/ombitasvir/ritonavir) and Exviera (dasabuvir). 2016 May. Available from:http://www.infohep.org/
78. Dore GJ, Conway B, Luo Y, et al. Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients:the MALACHITE-I/II trials. J Hepatol. 2016;64(1):19–28.
79. Scheiner B, Schwabl P, Steiner S, et al. Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease:a retrospective study. Medicine (Baltimore). 2016;95(27):e4061.
80. Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study):a combination phase 3 study. Lancet. 2015;386(10003):1537–1545.
81. Feld JJ, Jacobson IM, Sulkowski MS, et al. Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection. Liver Int. 2017;37(1):5–18.
82. Wang H-L, Lu X, Yang X, et al. Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b:systematic review and meta-analysis. J Gastroenterol Hepatol. 2017;32(1):45–52.
83. McEwan P, Ward T, Webster S, et al. Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b. Hepatol Res. 2016;46(5):423–433.
84. NATAP. New HCV drugs at AASLD, The Liver Meeting. Boston (MA). 2016 November.
85. Tapper EB, Bacon BR, Curry MP, et al. Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C:the Trio Health Study. J Viral Hepat. 2016;24(1):22–27.
86. Sogni P, Gilbert C, Lacombe K, et al. All-oral direct-acting antiviral regimens in HIV/hepatitis C virus–coinfected patients with cirrhosis are efficient and safe:real-life results from the prospective ANRS CO13–HEPAVIH cohort. Clin Infect Dis. 2016;63(6):763–770.
87. Klein MB, Saeed S, Yang H, et al. Cohort profile:the Canadian HIV-Hepatitis C Co-infection Cohort Study. Int J Epidemiol. 2010;39(5):1162–1169.
88. Grebely J, Alavi M, Micallef M, et al. Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics:the ETHOS Study. Addict. 2016;111(2):311–319.
89. Marcellin F, Fournier I, Carrieri MP, et al. ANRS HC26 & ANRS HC27 study groups. From first-generation hepatitis C virus protease inhibitors to direct-acting antivirals:self-reported symptoms as a warning signal for potential adverse events (ANRS HC26, ANRS HC27 trials). Eur J Gastroenterol Hepatol. 2016;28(6):733–734.
90. Midgard H, Weir A, Palmateer N, et al. HCV epidemiology in high-risk groups and the risk of reinfection. J Hepatol. 2016;65(1 Suppl):S33–45.
91. Saab S, Park SH, Mizokami M, et al. Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. Hepatol. 2016;63(4):1112–1119.
92. Ho SB, Monto A, Peyton A, et al. Efficacy of sofosbuvir plus ribavirin in veterans with hepatitis C virus genotype 2 infection, compensated cirrhosis, and multiple comorbidities. Clin Gastroenterol Hepatol. 2016;15(2):282-288.
93. Younossi ZM, Stepanova M, Chan HLY, et al. Patient-reported outcomes in Asian patients with chronic hepatitis C treated with ledipasvir and sofosbuvir. Medicine (Baltimore). 2016;95(9):e2702.
94. Higgs P, Wright C, Hellard M. Letter:new treatments for hepatitis C have implications for quality of life in people who inject drugs. Aliment Pharmacol Ther. 2016;43(7):840–841.